Specific Antiviral Drugs For COVID 19 Global Market Report 2025

Description

Specific antiviral drugs for COVID-19 are therapeutics specifically developed to target and disrupt the replication or activity of the SARS-CoV-2 virus, the causative agent of COVID-19. These medications function by interfering with vital viral processes such as entry into host cells, replication, or assembly, thereby helping to lessen the severity and duration of the illness.

These antiviral drugs are available in both tablet and injectable formulations. Tablets are compressed solid dosage forms containing a fixed amount of active pharmaceutical ingredients along with excipients, typically in a flat or oval shape. These medications are prescribed for use in hospitalized patients, individuals receiving outpatient care, as well as for preventive purposes. They fall into various pharmacological categories, including nucleoside analogues, protease inhibitors, RNA polymerase inhibitors, entry inhibitors, and monoclonal antibodies, and are administered via oral, intravenous, subcutaneous, or inhalation routes. The distribution channels for these drugs include hospital pharmacies, retail pharmacies, and other pharmaceutical outlets.

The specific antiviral drugs for COVID-19 market size has grown rapidly in recent years. It will grow from $13.00 billion in 2024 to $15.23 billion in 2025 at a compound annual growth rate (CAGR) of 17.1%. Growth during the historic period was driven by factors such as the surge in hospital admissions due to severe infections, increased governmental investment in antiviral development, rising demand for targeted treatment solutions over generic alternatives, heightened awareness of the benefits of early antiviral administration, and enhanced collaboration among pharmaceutical firms.

The specific antiviral drugs for COVID-19 market size is expected to see rapid growth in the next few years. It will grow to $28.43 billion in 2029 at a compound annual growth rate (CAGR) of 16.9%. Key drivers in the forecast period include greater emphasis on pandemic preparedness, expansion of clinical trial activities, heightened need for effective treatment options, increasing circulation of COVID-19 variants, and rising acceptance of orally administered antiviral medications. Notable trends expected to shape the market include the development of broad-spectrum antiviral solutions, use of AI technologies in drug development, progress in personalized antiviral treatment methods, innovations in combination therapies, and the application of genomic insights to counter viral mutations.

The rising number of COVID-19 cases is expected to propel the growth of the specific antiviral drugs for the COVID-19 market going forward. COVID-19 cases refer to individuals who tested positive for the SARS-CoV-2 virus, which causes COVID-19. The increase in cases is due to the emergence of new variants that spread more easily and can partially evade immunity from vaccines or past infections. Specific antiviral drugs for COVID-19 help reduce the severity and duration of the illness, improving patient outcomes and lowering the overall burden of COVID-19 cases. For instance, in May 2023, according to the Centers for Disease Control and Prevention, a US-based government agency, on average, COVID-19 deaths that included additional causes of death had 4.5 contributing conditions listed in 2022, compared to 4.2 in 2021. Therefore, the rising number of COVID-19 cases drives the growth of the specific antiviral drugs for the COVID-19 market.

Major companies operating in the specific antiviral drugs for the COVID-19 market are focusing on developing innovative therapies, such as oral antiviral therapies, to enhance treatment accessibility and effectiveness. Oral antiviral therapies are medications taken by mouth to inhibit the replication of viruses like COVID-19, offering a convenient and effective treatment option. For instance, in January 2022, Lupin Limited, an India-based pharmaceutical company, launched the antiviral drug Molnupiravir under the brand name Molnulup to treat high-risk adult patients with COVID-19. This oral medication is intended for adults with mild to moderate COVID-19 who are at risk of developing severe illness. Molnupiravir works by inhibiting the replication of the SARS-CoV-2 virus, thereby helping to lower the viral load and reduce the severity of the disease. It is most effective when started within five days of symptom onset and is especially beneficial for individuals with comorbid conditions such as obesity, advanced age, diabetes, or cardiovascular disease.

In July 2024, GSK plc, a UK-based pharmaceutical company, collaborated with CureVac to develop and commercialize next-generation mRNA vaccines for COVID-19 and influenza. This collaboration aims to develop and commercialize innovative mRNA vaccines for influenza and COVID-19 to improve global public health outcomes. CureVac N.V. is a Germany-based company that develops therapies based on messenger RNA (mRNA) technology.

Major players in the specific antiviral drugs for covid 19 market are Pfizer Inc., Johnson and Johnson, Roche Holding AG, Merck And Co. Inc., Novartis AG, GSK plc, Eli Lilly and Company, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc, Hetero Drugs Limited, Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Limited, Beximco Pharmaceuticals Limited, BioCryst Pharmaceuticals Inc., Atea Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., RedHill Biopharma Ltd., Aligos Therapeutics Inc., Synairgen plc

North America was the largest region in the specific antiviral drugs for COVID 19 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in specific antiviral drugs for COVID-19 report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the specific antiviral drugs for COVID-19 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The specific antiviral drugs for COVID-19 market consists of sales of host-directed antivirals, immunomodulators, fusion inhibitors, helicase inhibitors, and tmprss2 inhibitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Specific Antiviral Drugs For COVID 19 Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on specific antiviral drugs for covid 19 market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for specific antiviral drugs for covid 19 ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The specific antiviral drugs for covid 19 market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Tablet; Injection
2) By Indication: Hospitalized Patients; Non-Hospitalized Patients; Preventive Treatment
3) By Drug Class: Nucleoside Analogues; Protease Inhibitors; Ribonucleic Acid Polymerase Inhibitors; Entry Inhibitors; Monoclonal Antibodies
4) By Route Of Administration: Oral; Intravenous; Subcutaneous; Inhalation
5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels

Subsegments

1) By Tablet: Oral Antiviral Tablets; Combination Antiviral Tablets; Extended-Release Tablets
2) By Injection: Intravenous (IV) Antiviral Injections; Intramuscular (IM) Antiviral Injections; Subcutaneous Antiviral Injections
Companies Mentioned: Pfizer Inc.; Johnson and Johnson; Roche Holding AG; Merck And Co. Inc.; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r36081

1. Executive Summary

2. Specific Antiviral Drugs For COVID 19 Market Characteristics

3. Specific Antiviral Drugs For COVID 19 Market Trends And Strategies

4. Specific Antiviral Drugs For COVID 19 Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Specific Antiviral Drugs For COVID 19 Growth Analysis And Strategic Analysis Framework

5.1. Global Specific Antiviral Drugs For COVID 19 PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Specific Antiviral Drugs For COVID 19 Market Growth Rate Analysis
5.4. Global Specific Antiviral Drugs For COVID 19 Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Specific Antiviral Drugs For COVID 19 Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Specific Antiviral Drugs For COVID 19 Total Addressable Market (TAM)

6. Specific Antiviral Drugs For COVID 19 Market Segmentation

6.1. Global Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tablet
Injection
6.2. Global Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitalized Patients
Non-Hospitalized Patients
Preventive Treatment
6.3. Global Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Nucleoside Analogues
Protease Inhibitors
Ribonucleic Acid Polymerase Inhibitors
Entry Inhibitors
Monoclonal Antibodies
6.4. Global Specific Antiviral Drugs For COVID 19 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Intravenous
Subcutaneous
Inhalation
6.5. Global Specific Antiviral Drugs For COVID 19 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Other Distribution Channels
6.6. Global Specific Antiviral Drugs For COVID 19 Market, Sub-Segmentation Of Tablet, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Antiviral Tablets
Combination Antiviral Tablets
Extended-Release Tablets
6.7. Global Specific Antiviral Drugs For COVID 19 Market, Sub-Segmentation Of Injection, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intravenous (IV) Antiviral Injections
Intramuscular (IM) Antiviral Injections
Subcutaneous Antiviral Injections

7. Specific Antiviral Drugs For COVID 19 Market Regional And Country Analysis

7.1. Global Specific Antiviral Drugs For COVID 19 Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Specific Antiviral Drugs For COVID 19 Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Specific Antiviral Drugs For COVID 19 Market

8.1. Asia-Pacific Specific Antiviral Drugs For COVID 19 Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Specific Antiviral Drugs For COVID 19 Market

9.1. China Specific Antiviral Drugs For COVID 19 Market Overview
9.2. China Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Specific Antiviral Drugs For COVID 19 Market

10.1. India Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Specific Antiviral Drugs For COVID 19 Market

11.1. Japan Specific Antiviral Drugs For COVID 19 Market Overview
11.2. Japan Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Specific Antiviral Drugs For COVID 19 Market

12.1. Australia Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Specific Antiviral Drugs For COVID 19 Market

13.1. Indonesia Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Specific Antiviral Drugs For COVID 19 Market

14.1. South Korea Specific Antiviral Drugs For COVID 19 Market Overview
14.2. South Korea Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Specific Antiviral Drugs For COVID 19 Market

15.1. Western Europe Specific Antiviral Drugs For COVID 19 Market Overview
15.2. Western Europe Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Specific Antiviral Drugs For COVID 19 Market

16.1. UK Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Specific Antiviral Drugs For COVID 19 Market

17.1. Germany Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Specific Antiviral Drugs For COVID 19 Market

18.1. France Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Specific Antiviral Drugs For COVID 19 Market

19.1. Italy Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Specific Antiviral Drugs For COVID 19 Market

20.1. Spain Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Specific Antiviral Drugs For COVID 19 Market

21.1. Eastern Europe Specific Antiviral Drugs For COVID 19 Market Overview
21.2. Eastern Europe Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Specific Antiviral Drugs For COVID 19 Market

22.1. Russia Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Specific Antiviral Drugs For COVID 19 Market

23.1. North America Specific Antiviral Drugs For COVID 19 Market Overview
23.2. North America Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Specific Antiviral Drugs For COVID 19 Market

24.1. USA Specific Antiviral Drugs For COVID 19 Market Overview
24.2. USA Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Specific Antiviral Drugs For COVID 19 Market

25.1. Canada Specific Antiviral Drugs For COVID 19 Market Overview
25.2. Canada Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Specific Antiviral Drugs For COVID 19 Market

26.1. South America Specific Antiviral Drugs For COVID 19 Market Overview
26.2. South America Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Specific Antiviral Drugs For COVID 19 Market

27.1. Brazil Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Specific Antiviral Drugs For COVID 19 Market

28.1. Middle East Specific Antiviral Drugs For COVID 19 Market Overview
28.2. Middle East Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Specific Antiviral Drugs For COVID 19 Market

29.1. Africa Specific Antiviral Drugs For COVID 19 Market Overview
29.2. Africa Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Specific Antiviral Drugs For COVID 19 Market Competitive Landscape And Company Profiles

30.1. Specific Antiviral Drugs For COVID 19 Market Competitive Landscape
30.2. Specific Antiviral Drugs For COVID 19 Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson and Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Specific Antiviral Drugs For COVID 19 Market Other Major And Innovative Companies

31.1. GSK plc
31.2. Eli Lilly and Company
31.3. Gilead Sciences Inc.
31.4. Regeneron Pharmaceuticals Inc
31.5. Hetero Drugs Limited
31.6. Sun Pharmaceutical Industries Limited
31.7. Shionogi and Co. Ltd.
31.8. Cipla Limited
31.9. Beximco Pharmaceuticals Limited
31.10. BioCryst Pharmaceuticals Inc.
31.11. Atea Pharmaceuticals Inc.
31.12. Enanta Pharmaceuticals Inc.
31.13. RedHill Biopharma Ltd.
31.14. Aligos Therapeutics Inc.
31.15. Synairgen plc

32. Global Specific Antiviral Drugs For COVID 19 Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Specific Antiviral Drugs For COVID 19 Market

34. Recent Developments In The Specific Antiviral Drugs For COVID 19 Market

35. Specific Antiviral Drugs For COVID 19 Market High Potential Countries, Segments and Strategies

35.1 Specific Antiviral Drugs For COVID 19 Market In 2029 - Countries Offering Most New Opportunities
35.2 Specific Antiviral Drugs For COVID 19 Market In 2029 - Segments Offering Most New Opportunities
35.3 Specific Antiviral Drugs For COVID 19 Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer